A Phase 1, Two-Part, Open-Label Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of Single Ascending Doses of APL-1501 Extended Release (ER) Capsules Compared to APL-1202 Immediate Release (IR) Tablets in Healthy Volunteers (Part A) and Multiple Ascending Doses of APL-1501 ER Capsules Compared to APL-1202 IR Tablets in Healthy Volunteers (Part B)
Latest Information Update: 18 Sep 2023
At a glance
- Drugs APL-1501 (Primary) ; Nitroxoline (Primary)
- Indications Bladder cancer
- Focus Adverse reactions
- Sponsors Jiangsu Yahong Pharmaceutical Technology
Most Recent Events
- 18 Sep 2023 New trial record